Immuneed

CARPA can trigger clinical holds and dose delays, and unintended complement activation is the culprit. Our article covers where CARPA comes from, which modalities carry the risk, and what human whole blood testing shows that serum assays miss.

Most preclinical complement safety assessments are still performed using methods with well-established limitations. With ID.Flow®, you study drug-induced immune reactions directly in freshly donated human blood during non-clinical development. You gain more relevant safety and efficacy data, reduce animal use, and improve the translatability of your preclinical findings to clinical outcomes.

Basal activation in static assays can obscure the signal you're actually trying to measure. With ID.Flow®, you study drug-induced immune reactions directly in freshly donated human blood during non-clinical development. You gain more relevant safety and efficacy data, reduce animal use, and improve the translatability of your preclinical findings to clinical outcomes.

Clean baseline and direct translational relevance. Full complement assessment done in one experimental run. With ID.Flow®, you study every complement response in one run, using freshly donated human whole blood. You get clean baselines, direct translational relevance, and richer safety data earlier - so you can predict drug‑induced immune reactions, reduce animal use, and bring more confidence to non‑clinical decisions.

No time to read blog articles to understand the full landscape of complement assessment in nonclinical development? We put it in 5 steps.

Measure C3a, C5a, Bb and platelet activation simultaneously in ID.Flow®. Cover classical, alternative, and terminal pathway activation, enabling CARPA risk assessment. With ID.Flow®, you study every complement response in one run, using freshly donated human whole blood. You get clean baselines, direct translational relevance, and richer safety data earlier - so you can predict drug‑induced immune reactions, reduce animal use, and bring more confidence to non‑clinical decisions.